Cadence Capital Management LLC Acquires 150,325 Shares of Champions Oncology Inc (CSBR)

Cadence Capital Management LLC increased its holdings in shares of Champions Oncology Inc (NASDAQ:CSBR) by 122.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 273,335 shares of the biotechnology company’s stock after purchasing an additional 150,325 shares during the period. Cadence Capital Management LLC’s holdings in Champions Oncology were worth $2,676,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of Champions Oncology by 656.2% in the third quarter. BlackRock Inc. now owns 123,540 shares of the biotechnology company’s stock worth $2,158,000 after acquiring an additional 107,202 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Champions Oncology in the third quarter worth $2,162,000. Vanguard Group Inc. boosted its holdings in shares of Champions Oncology by 51.4% in the third quarter. Vanguard Group Inc. now owns 231,150 shares of the biotechnology company’s stock worth $4,038,000 after acquiring an additional 78,428 shares during the period. Vanguard Group Inc boosted its holdings in shares of Champions Oncology by 51.4% in the third quarter. Vanguard Group Inc now owns 231,150 shares of the biotechnology company’s stock worth $4,038,000 after acquiring an additional 78,428 shares during the period. Finally, ClariVest Asset Management LLC boosted its holdings in shares of Champions Oncology by 29.6% in the fourth quarter. ClariVest Asset Management LLC now owns 39,800 shares of the biotechnology company’s stock worth $311,000 after acquiring an additional 9,100 shares during the period. Hedge funds and other institutional investors own 53.25% of the company’s stock.

A number of equities analysts have recently commented on the company. Zacks Investment Research raised Champions Oncology from a “strong sell” rating to a “hold” rating in a report on Monday, March 18th. National Securities assumed coverage on Champions Oncology in a report on Wednesday, February 27th. They issued a “buy” rating and a $17.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Champions Oncology presently has an average rating of “Buy” and a consensus price target of $13.67.

Champions Oncology stock opened at $8.50 on Friday. Champions Oncology Inc has a one year low of $3.92 and a one year high of $17.90. The firm has a market capitalization of $98.73 million, a PE ratio of -60.71 and a beta of 1.42.

COPYRIGHT VIOLATION NOTICE: “Cadence Capital Management LLC Acquires 150,325 Shares of Champions Oncology Inc (CSBR)” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/18/cadence-capital-management-llc-acquires-150325-shares-of-champions-oncology-inc-csbr.html.

About Champions Oncology

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Read More: Stock Symbol

Want to see what other hedge funds are holding CSBR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Champions Oncology Inc (NASDAQ:CSBR).

Institutional Ownership by Quarter for Champions Oncology (NASDAQ:CSBR)

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.